<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>17972380</identifier>
<setSpec>1405-9940</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Chávez, Laura Leticia Rodríguez</dc:author>
<dc:description xml:lang="en">Multiple drugs are helpful for rate control in different tachyarrhythmias, in particular atrial fibrillation (AF). Betablockers (betaB) and calcium channel blockers have been used as monotherapy or as adjunctive therapy to antiarrhythmics for mantaining an acceptable ventricular rate. In recent years new concepts about auricular remodelation process as a consequence of AF has shown benefits with drugs as angiotensin-renin system blockers (ARSB) like angiotensin conversing enzime inhibitors (ACEI) and angiotensin receptor blockers (ARB). In this article it will be reviewed the benefits of rate control in AF by using betaB and calcium channel blockers and also the benefits in atrial remodelation process and the prevention of AF with ARSB drugs.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>2007 Apr-Jun </dc:date>
<dc:title xml:lang="es">Fármacos para control de la frecuencia ventricular y fármacos no-antiarrítmicos en fibrilación auricular.</dc:title>
<dc:title xml:lang="en">[Drugs for heart rate control and non-antiarrhythmic drugs in atrial fibrillation].</dc:title>
<dc:publisher>Archivos de cardiologia de Mexico</dc:publisher>
</metadata>
</record>
</pubmed-document>
